Description: Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.
Home Page: www.xintela.se
Scheeletorget 1
Lund,
223 81
Sweden
Phone:
46 4 62 75 65 00
Officers
| Name | Title |
|---|---|
| Mr. Gregory Batcheller B.Sc., J.D., L.L.M., LLM | Exec. Chairman |
| Mr. Gunnar Telhammar | CFO & Fin. Director |
| Dr. Thomas Areschoug Ph.D. | Chief Bus. Officer |
| Dr. Per Norlen | Chief Medical Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 11.5172 |
| Price-to-Sales TTM: | 5115.129 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |